These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21586917)

  • 1. Neurobiological background for the development of new drugs in schizophrenia.
    López-Muñoz F; Álamo C
    Clin Neuropharmacol; 2011; 34(3):111-26. PubMed ID: 21586917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex.
    Amargós-Bosch M; Adell A; Artigas F
    J Neurochem; 2007 Jul; 102(2):550-61. PubMed ID: 17394545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-Target Approach for Drug Discovery against Schizophrenia.
    Kondej M; Stępnicki P; Kaczor AA
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30309037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of prolactin in antipsychotic-mediated association of schizophrenia and type 2 diabetes.
    Oberweis B; Gragnoli C
    J Cell Physiol; 2012 Aug; 227(8):3001-6. PubMed ID: 22105468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs in development for the treatment of schizophrenia.
    Emsley R
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1103-18. PubMed ID: 19589093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.
    Svensson TH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1145-58. PubMed ID: 14642973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New pharmacological approaches to the treatment of schizophrenia].
    Uzbay IT
    Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive modulators of AMPA receptors as a potential treatment for schizophrenia.
    Danysz W
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1062-6. PubMed ID: 12186268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of serotonin receptors in the action of atypical antipsychotic drugs.
    Meltzer HY; Massey BW
    Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains.
    Noga JT; Hyde TM; Herman MM; Spurney CF; Bigelow LB; Weinberger DR; Kleinman JE
    Synapse; 1997 Nov; 27(3):168-76. PubMed ID: 9329152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.